XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2023). On theSindex it has a DataRank of 0.729. It has been cited 19 times, with 19 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0.279
From 15 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 19 citers.
Xilio Therapeutics, Inc
Grant: N/A
National Institutes of Health
Grant: P30CA033572
National Institutes of Health
Grant: 5P30CA033572-27
Developmental Funds
FWCI
3.10
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals